Monday, February 26, 2024
Tonix is a biopharmaceutical company commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system disorders. Tonix plans to submit an NDA to the FDA for Tonmya, which has completed two positive Phase 3 studies for the management of fibromyalgia, including a meeting with FDA in the second half of 2024. TNX-102 SL is being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and positive topline results from a proof-of-concept study were reported in the third quarter of 2023. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired in June 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.
CEO/Top Company Official
Seth Lederman, M.D. Co-Founder, CEO & Chairman
Lead Product in Development
Development Phase of Primary Product
NDA Preparation/In Review